Exenatide and the treatment of patients with Parkinson's disease - Wikidata - awgldk - TriplyDB

Exenatide and the treatment of patients with Parkinson's disease

Exenatide and the treatment of patients with Parkinson's disease

http://www.wikidata.org/entity/Q30540208

about

Regulation of glucose homeostasis by GLP-1 Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson's Disease Emerging preclinical pharmacological targets for Parkinson's disease New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease BDNF mediates adaptive brain and body responses to energetic challenges Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide GLP-1 improves neuropathology after murine cold lesion brain trauma The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease.Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines.Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis.Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes.Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease.Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients.Glucagon peptide-like 1 receptor (GLP-1R) expression per se: a new insight into neurodegenerative disease?Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4.Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson's disease.Acylated but not des-acyl ghrelin is neuroprotective in an MPTP mouse model of Parkinson's disease.A new approach to disease-modifying drug trials in Parkinson's disease Combined Diffusion Tensor Imaging and Arterial Spin Labeling as Markers of Early Parkinson's disease.Plasma metabolomic profiles in association with type 2 diabetes risk and prevalence in Chinese adults.Deciphering Brain Insulin Receptor and Insulin-Like Growth Factor 1 Receptor Signalling.Diabetes negatively affects cortical and striatal GABAergic neurons: an effect that is partially counteracted by exendin-4.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.

P2860

Q24563430-0EB48CBD-EE00-4441-8525-1C1A1A0B7C1E Q26750370-70990C28-9CE2-492A-9638-2A408F3BC30C Q26764724-A3FFA137-9A7A-4CE9-9C2F-5CEAFC5FDEC5 Q26866194-3C5B60FC-3AD3-4DB6-8A19-BEE09A377C26 Q26995786-1467AE3D-E003-4D56-BF46-3439C6BD7076 Q26999386-EF011B13-C914-42AE-A508-709EFB5C8E41 Q27003253-A003CA54-5636-4FEE-B5E8-DEC2B98DD72A Q27008997-46F683BD-9EA3-4C40-B36E-A5BDED882ED8 Q27012801-AB17CF07-5A66-40BA-8245-2EFEC17E3E84 Q27311651-A623967E-BD9F-4228-992D-18BA5F57ED2F Q27693260-8DDE34C9-A23B-476A-A079-F42F9E821653 Q28067465-05D08B36-7088-4843-A0C8-F0918D3CD2FA Q28081671-96FA2010-F0C5-4108-BA09-786F41CCF600 Q28651569-2FC13942-9CDE-45EC-92DC-297E802929F1 Q33600053-6B801B77-E482-4CE9-8C8F-129223A57049 Q33628048-05BC9B42-92C8-4E16-A070-31DACE03F1A1 Q33708923-55C1EA6F-A67F-4E41-A717-37124CE5C958 Q33731321-A854E399-3D92-4B78-9769-7A6EFC8B5FF6 Q33734563-5CACFDA4-1578-4E5D-BE7E-24CA6E310416 Q33783000-5F8F843A-2CCF-4639-9913-CED1193E190B Q34287243-A83EB981-8705-405C-908B-EFE62B2FA602 Q34362412-86959045-E7BB-406D-AF80-2749131C9B39 Q34476077-B537951E-127D-4742-8335-4F280D1AC5C0 Q35078279-A1791ACF-D630-4FC7-B607-49DCA5E7828D Q35129144-293EFF4E-CCF3-46D2-B54D-9CE5CD8C3EA1 Q35183919-E65A5FEF-E5D3-4192-B1DC-F76F335F7C3D Q35969658-C92D7A66-A38E-4F6E-927A-6215BECE362D Q36164724-1BE0B70E-C28E-4D95-828C-7D16597745E4 Q36279695-2486AF0A-A8B9-4222-B9FC-F25B61B98FF4 Q36406821-626285C4-3D13-4AF0-9946-37442E50E119 Q36471528-EC84E05A-87B2-4722-A50C-557F9ADAAAB9 Q36737512-EBBF0700-8CE1-4E50-B961-972FC7E9E724 Q36813540-CB01E13E-DE3B-4FF0-B6A9-4C89541722C1 Q36890999-CF1A5D4F-028B-41FD-AE88-F5C10436C8F1 Q37267022-B01158ED-C475-4C11-B389-A11C5538BC98 Q37403973-18A4480B-BCE3-430B-812E-385ED1BB4365 Q37456221-B6241E14-525A-44CA-812B-B6EA1BFCBC13 Q37473323-B6CE3225-74E8-4A69-9F69-05F9A48C81E7 Q37506492-85F397E6-AAEA-4218-9783-57811FC90EF8 Q37568754-8CC0B710-80B5-407B-9721-D67ECD9CF213

P2860

Exenatide and the treatment of patients with Parkinson's disease

http://www.wikidata.org/entity/Q30540208

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Exenatide and the treatment of patients with Parkinson's disease

@ast

Exenatide and the treatment of patients with Parkinson's disease

@en

type

label

Exenatide and the treatment of patients with Parkinson's disease

@ast

Exenatide and the treatment of patients with Parkinson's disease

@en

prefLabel

Exenatide and the treatment of patients with Parkinson's disease

@ast

Exenatide and the treatment of patients with Parkinson's disease

@en

P1433

Q30540208-1ACF4B07-582B-464C-A7CA-DAC0948A8483

P1476

Q30540208-6ACFE14F-D7B0-46AE-99EF-B64097C48CEB

P2093

Q30540208-1CD5ECC7-3771-4ED4-8B4D-B4E47FA8FE0E

Q30540208-2FA2CB51-9BB6-4819-A7D5-335E3DA72752

Q30540208-45CC2898-5F66-4AEF-9019-9968805164DE

Q30540208-4D6495C8-2976-4E25-A72D-796E7D6ECB33

Q30540208-AB00B917-0008-487C-9DAF-283EFADFAF84

Q30540208-CDE57FEF-5E88-4739-B78E-B8E759AEC445

Q30540208-CE744EB2-D5B7-4CC7-94F6-BD84B45A69F1

Q30540208-EB07B838-F581-4AA6-B604-95A60AEF21AF

P2860

Q30540208-2A5514BC-067E-4496-97A9-D93397118656

Q30540208-3E108542-6C81-47A8-A448-A1A44C615157

Q30540208-4899F1AA-E2CB-4084-BDB0-D01F8613087E

Q30540208-4901F559-F3D3-410E-9D93-A1DB9B7E6BAE

Q30540208-53E36FB9-730E-4188-B4FA-4CE2DCF0705A

Q30540208-6203087B-D140-4207-BA77-483E6D0302F1

Q30540208-692D3380-156A-4200-B573-F04B68457598

Q30540208-6F4F1E3F-FB5A-40F9-8DD5-DA31510F1007

Q30540208-7E41C945-3D86-444E-9799-95C204C267B6

Q30540208-82097D4B-3E09-4445-A34C-C9C2FABF45CC

P304

Q30540208-868D69AA-3743-4933-A89B-7650A922B7FA

P31

Q30540208-EDD8AB2B-68C3-40C8-9D81-1683B6E1E0BA

P356

Q30540208-0A9F0F28-C8A2-41F7-9A3F-FFF9EBF6C165

P407

Q30540208-44D9247A-3C37-4344-8FEA-E5FD764CEDA2

P433

Q30540208-9F564077-5CA0-42B4-B2EA-A2281440BE3B

P478

Q30540208-62547AC9-AAAB-4554-9642-DE591AC2C367

P50

Q30540208-68694A83-9FBC-4765-9516-319372CB3C54

Q30540208-808FA2EA-023D-4E4E-B540-38D53D67DE0F

Q30540208-DF934359-4A7D-485B-B40A-E0716EA5CFCD

Q30540208-ED3F3DC2-3E70-4124-A4EB-29AC53BF5741

P577

Q30540208-749D5646-FA4A-4822-A051-70FB10162C8B

P5875

Q30540208-75CA143F-A122-4172-BABB-2C281D0E55B1

P698

Q30540208-7F171D3F-2644-413F-AC80-49ADF71C06B3

P921

Q30540208-8ACB74FB-9AA6-4187-A038-D4FD5A47BBF5

Q30540208-EF0E7DA9-44CD-4266-8F8B-EA018A4FBF80

P932

Q30540208-D09336D1-8966-4BDE-B5FE-FC3D2B72D19E

P356

P1433

Journal of Clinical Investigation

P1476

Exenatide and the treatment of patients with Parkinson's disease

@en

P2093

Iciar Aviles-Olmos

http://www.w3.org/2001/XMLSchema#string

John Dickson

http://www.w3.org/2001/XMLSchema#string

Peter Ell

http://www.w3.org/2001/XMLSchema#string

Peter Whitton

http://www.w3.org/2001/XMLSchema#string

Richard Wyse

http://www.w3.org/2001/XMLSchema#string

Therese Soderlund

http://www.w3.org/2001/XMLSchema#string

Tom Isaacs

http://www.w3.org/2001/XMLSchema#string

Zinovia Kefalopoulou

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinson's disease, insulin resistance and novel agents of neuroprotection

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

Proof of Principle studies.

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.

Why have we failed to achieve neuroprotection in Parkinson's disease?

Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.

P304

2730-2736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI68295

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Atbin Djamshidian

Andrew John Lees

Thomas Foltynie

Patricia Limousin

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237004312

http://www.w3.org/2001/XMLSchema#string

P698

23728174

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3668846

http://www.w3.org/2001/XMLSchema#string